INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
GS
Corporate insider

Gheuens Sarah

Chief Medical OfficerCIK 0001881190

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 3
Max Insider Score11
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$197K
7,866 sh
Oct 26, 2026Oct 28, 2026
traded Oct 26, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    AGIOS PHARMACEUTICALS, INC.Chief Medical Officer · Oct 23, 2026
11
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$296K
7,866 sh
Oct 26, 2026
Oct 28, 2026
traded Oct 26, 2026
+2d
SEC FORM 4

Evidence

7
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
7,866 sh
Oct 26, 2026Oct 28, 2026
traded Oct 26, 2026
+2dSEC FORM 4

Evidence

3
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
1,489 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

0
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$37K
1,489 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

8
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$56K
1,489 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

0
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$13K
500 sh
Oct 22, 2026Oct 23, 2026
traded Oct 22, 2026
+1dSEC FORM 4

Evidence

1
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$19K
500 sh
Oct 22, 2026Oct 23, 2026
traded Oct 22, 2026
+1dSEC FORM 4

Evidence

0
GS
Gheuens SarahChief Medical Officer
AGIOAGIOS PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
500 sh
Oct 22, 2026Oct 23, 2026
traded Oct 22, 2026
+1dSEC FORM 4

Evidence